Detalhe da pesquisa
1.
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
Invest New Drugs
; 37(4): 755-762, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31172443
2.
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Lancet Oncol
; 11(10): 962-72, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20851682
3.
Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
J Clin Endocrinol Metab
; 105(7)2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32421817
4.
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Thyroid
; 30(9): 1254-1262, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538690
5.
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Clin Cancer Res
; 24(4): 744-752, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29138343
6.
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
J Clin Oncol
; 35(29): 3315-3321, 2017 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817373
7.
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
J Clin Endocrinol Metab
; 99(5): 1687-93, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24606083
8.
Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma.
Am J Cancer Res
; 3(4): 390-401, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23977448
9.
Systemic therapeutic approaches to advanced thyroid cancers.
Am Soc Clin Oncol Educ Book
; : 389-92, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-24451769
10.
Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Mol Cancer Ther
; 11(10): 2105-15, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22826467
11.
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
J Clin Endocrinol Metab
; 97(9): 3179-84, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22774206
12.
Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.
Am J Manag Care
; 18(5): e162-7, 2012 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22694109
13.
Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.
J Oncol Pract
; 8(3 Suppl): e1s-5s, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22942830
14.
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
J Clin Oncol
; 28(19): e312-3, 2010 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20516434